Idioma:

Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma

Kulason, Kay O ; Schneider, Julia R ; Chakraborty, Shamik ; Filippi, Christopher G ; Pramanik, Bidyut ; Wong, Tamika ; Fralin, Sherese ; Tan, Karissa ; Ray, Ashley ; Alter, Rachel A ; Ortiz, Rafael ; Demopoulos, Alexis ; Langer, David J ; Boockvar, John A

Journal of experimental therapeutics & oncology, 2018-05, Vol.12 (3), p.223 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por

Enviar para

Título:
Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma
Autor: Kulason, Kay O ; Schneider, Julia R ; Chakraborty, Shamik ; Filippi, Christopher G ; Pramanik, Bidyut ; Wong, Tamika ; Fralin, Sherese ; Tan, Karissa ; Ray, Ashley ; Alter, Rachel A ; Ortiz, Rafael ; Demopoulos, Alexis ; Langer, David J ; Boockvar, John A
Assuntos: Angiography, Digital Subtraction ; Antineoplastic Agents, Alkylating - administration & dosage ; Antineoplastic Agents, Immunological - administration & dosage ; Blood-Brain Barrier - drug effects ; Blood-Brain Barrier - metabolism ; Blood-Brain Barrier - pathology ; Brain Neoplasms - metabolism ; Brain Neoplasms - pathology ; Brain Neoplasms - therapy ; Cerebral Angiography - methods ; Cetuximab - administration & dosage ; Chemoradiotherapy, Adjuvant ; Chemotherapy, Adjuvant ; Craniotomy ; Dacarbazine - administration & dosage ; Dacarbazine - analogs & derivatives ; Dose Fractionation, Radiation ; Female ; Glioblastoma - metabolism ; Glioblastoma - pathology ; Glioblastoma - therapy ; Humans ; Infusions, Intra-Arterial ; Magnetic Resonance Imaging ; Mannitol - therapeutic use ; Middle Aged ; Temozolomide ; Treatment Outcome
É parte de: Journal of experimental therapeutics & oncology, 2018-05, Vol.12 (3), p.223
Descrição: We describe the first case of a novel treatment for a newly diagnosed glioblastoma (GBM) using superselective intraarterial cerebral infusion (SIACI) of cetuximab after osmotic disruption of the blood-brain barrier (BBB) with mannitol. A 51year-old female underwent craniotomy for removal of a right frontal GBM. Pathology confirmed EGFR amplification, and she underwent three treatments of SIACI of cetuximab to the tumor site. The first treatment was given within a week of starting standard of care chemoradiation (Stupp protocol), which is a combination of radiation treatment (2 Gy per/ day x 30 days, total of 60 Gy) and oral temozolomide (75 mg/m ). The second and third SIACI of cetuximab were administered 3 and 6 months later, while the patient continued on maintenance temozolomide. Post-radiation changes on MRI were stable, and there were no signs of recurrence at 4 and 6 months post-resection. Herein, we detail the technical aspects of this novel treatment paradigm and suggest that SIACI of cetuximab after BBB disruption using mannitol, combined with the standard of care chemoradiation therapy, may be an effective treatment method for newly diagnosed EGFR amplified glioblastoma.
Editor: United States
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 10 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma

Kulason, Kay O ; Schneider, Julia R ; Chakraborty, Shamik ; Filippi, Christopher G ; Pramanik, Bidyut ; Wong, Tamika ; Fralin, Sherese ; Tan, Karissa ; Ray, Ashley ; Alter, Rachel A ; Ortiz, Rafael ; Demopoulos, Alexis ; Langer, David J ; Boockvar, John A

United States

Buscando em bases de dados remotas. Favor aguardar.